POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：1
|
作者：
Matasar, Matthew J. [1 ]
Haioun, Corinne [2 ]
Sancho, Juan-Manuel [3 ]
Viardot, Andreas [4 ]
Hirata, Jamie [5 ]
Perretti, Thomas [6 ]
Musick, Lisa [5 ]
McMillan, Andrew K. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Groupe Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[5] Genentech Inc, South San Francisco, CA USA
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3568
引用
收藏
页数：5
相关论文
共 50 条
  • [1] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Haioun, Corinne
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    McMillan, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
    McMillan, Andrew K.
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    Haioun, Corinne
    [J]. BLOOD, 2019, 134
  • [3] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    [J]. CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [4] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Izquierdo, Antonia Rodriguez
    Martin, Eva Maria Donato
    Garcia-Sancho, Alejandro Martin
    Sandoval-Sus, Jose David
    Tilly, Herve
    Vandenberghe, Elizabeth
    Hirata, Jamie
    Choudhry, Priya
    Chang, Yi Meng
    Musick, Lisa
    McMillan, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    [J]. DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [6] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    [J]. BLOOD, 2019, 134
  • [7] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [8] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [9] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    [J]. SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [10] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
12345